Type 1 diabetes mellitus (T1DM) is a single-cell disorder in which insulin-secreting b-cells in pancreatic islets of langerhans are irreversibly destroyed. 1) Because diabetes is caused by the loss of a single cell type, in recent years, cellular replacement therapy for DM, especially T1DM, has received much attention. However, there are insufficient organ donors and the recipient has to take a risk of anti-rejection therapies.
2) More recently, additional efforts have focused on the use of both autologous and allogeneic stem cells as sources of new islets. [3] [4] [5] Bone marrow (BM) contains hematopoietic stem cells and mesenchymal stem cells (MSCs), both of which exhibit considerable developmental plasticity. 1) Some advances have been made to achieve spontaneous or induced differentiation of MSC into insulin producing cells. Although it is possible to induce in vitro expression of b-cell specific genes in murine and human BM-MSC but insulin secretion of these differentiated cells is very low. 4) Several in vitro studies have demonstrated that rodent BM stem cells can adopt an insulin-expressing phenotype, 6) and driving the phenotype of human BM stem cells by the forced expression of b-cell transcription factors generated cells capable of glucose responsive insulin secretion. 7) Several in vivo studies demonstrated that BM-derived cells transplanted into diabetic mice contribute to endocrine pancreatic regeneration. 6, [8] [9] [10] [11] More recent reports suggest that BM stem cells reversed experimental diabetes in vivo by enhancing the regeneration and survival of endogenous b-cells rather than repopulating the islets with trans-differentiated b-cells. 12, 13) In addition, hematopoietic stem cells and mesenchymal stem cells isolated from umbilical cord blood differentiated in vitro into insulin expressing cells. [2] [3] [4] [14] [15] [16] [17] [18] In this study, we induced the BM-MSCs into endoderm and hepatic cells and then transplanted these cells into streptozotocin (STZ)-induced diabetic mice.
MATERIALS AND METHODS

Mice and Induction of Experimental Diabetes
Female inbred BALB/c mice (6-8 weeks old) were purchased from the Pasteur Institute, Tehran, Iran. They were given sterilized water and autoclaved standard mouse chow throughout the study. Diabetes was induced in the mice by a single dose of STZ (200 mg/kg, Sigma, U.S.A.). STZ was solubilized in the sodium citrate buffer, pH 4.5, and injected within 15 min of preparation; control (non-diabetic group) mice received citrate buffer alone.
Isolation and Expansion of Mouse MSCs BM cells from 6-8 weeks old BALB/c mice were flushed from the medullary cavities of femurs and tibias and cultured as previously described. 19) In this study, previously characterized mouse MSCs were used.
19) The cells were negative for CD31, CD34, CD11b, CD45, c-Kit, Vcam-1, and CD135 antigens, and positive for CD44, Sca-1, and Thy1.2 (CD90), in addition, the potential of the isolated cells to differentiate into osteogenic and adipogenic lineages was examined. 19) Induction of Hepatic Differentiation To induce hepatic differentiation, mouse MSCs were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 50 ng/ml hepatocyte growth factor (HGF, PeproTech EC) and 10 ng/ml fibroblast growth factor 4 (FGF-4, PeproTech EC) for 2 weeks.
20)
Total RNA Isolation and Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Analysis For RT-PCR analysis, total cellular RNA was extracted by TRI-reagent (Sigma). Synthesis of cDNA was carried out with M-MuLV reverse transcriptase (RT) and random hexamer as the primer, according to the manufacturer's instructions (Fermentas). PCR amplification was performed by standard procedure with Taq DNA Polymerase (Fermentas) with denaturation at 94°C for 15 s, annealing at 60°C for 45 s according to the primers, and extension at 72°C for 45 s. The number of cycles varied between 30 and 40, depending on the abundance of particular mRNA. The primers and product lengths are listed in Table 1 .
Transplantation of MSCs-Derived Early Hepatic Cells Blood glucose levels were monitored using the Accu-Chek glucose detector (Accu-Chek Active blood glucose meter; F. Hoffmann-La Roche, Basel, Switzerland) after fast. Within 3-4 weeks of STZ injection, all BALB/c mice became hyperglycemic, with blood glucose levels Ͼ300 mg/dl. MSCs were treated with thymidine analogue, 5-bromo-2Ј-deoxyuridine (BrdU; Sigma) 24 h before transplantation. 1ϫ10 5 BMMSCs, 1ϫ10 6 BM-MSCs and 1ϫ10 6 induced BM-MSCs from normal BALB/c mice were transplanted into the diabetic mice through a tail vein. Five diabetic mice received sham surgery and injection of phosphate-buffered saline (PBS) as a control. Six to seven mice were used for each group and the experimental protocol is shown in Fig. 1A .
Histology and Immunohistochemistry Formalin-fixed paraffin-embedded pieces of the pancreas were cut into 4-mm-thick sections and mounted on glass slides coated with poly-L-lysine. The sections were deparaffinized in xylene and rehydrated. The sections were stained with hematoxylin and eosin. For BrdU staining, sections were pretreated and incubated overnight with the mouse monoclonal anti-BrdU antibody (1 : 50). Labeled cells were visualized with the matched secondary antibody with PE (1 : 200). For immunohistochemistry, the sections were incubated in blocking buffer (0.1 M PBS containing 0.5% normal goat serum, 0.2% Triton X-100) for 1 h, and thereafter in primary antibody for 1 h at 37°C diluted in blocking buffer. The antibodies used in this study were mouse monoclonal anti-insulin antibody (1 : 200 R&D Systems). The secondary antibody used was immunoglobulin G (IgG) fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse antibody (1 : 100, Sigma). Incubation with the secondary antibody was performed at 37°C for 30 min. Finally, the sections were counterstained with 4Ј-6-diamidino-2-phenylindole (DAPI) and mounted.
ELISA for Measuring Serum Insulin Serum insulin was quantified by mouse insulin-specific enzyme-linked immunosorbant assay (ELISA) kit. Upon euthanasia, whole blood was collected from retro-orbital vein, and sera were isolated by centrifugation. Insulin levels were measured by rat/mouse insulin ELISA kit (Linco Research, St. Charles, MO, U.S.A.) according to the manufacturer's instructions.
Blood Glucose Monitoring Blood glucose levels were determined by blood samples from the tail tip weekly using a glucometer (AccuChek, Roche Diagnostics, Indianapolis, IN, U.S.A,).
Intraperitoneal Glucose Tolerance Test (IGT) To identify impaired glucose tolerance, mice were fasted overnight for at least 14 h and were injected with glucose at a dose of 2 g/kg body weight, intraperitoneally (i.p.). Venous serum glucose was checked before, and 30 and 60 min after the injection.
Statistical Analysis Data are presented as meanϮS.D. Statistical analysis of the data was performed by one-way ANOVA followed by Tukey's test. For survival analysis logrank test was used. A p-value of Ͻ0.05 was regarded as significant.
RESULTS
Induction of Experimental Diabetes
In this study, we have developed a high-dose STZ diabetes model. The blood glucose levels of Ͼ300 mg/dl were observed within 3-4 R: GTT TTG GGG ATG GGC ACT G Glucose-6-phosphatase (G 6 P) F: CAG GAC TGG TTC ATC CTT 60°C 209 bp NM_008061.3 R: GTT GCT GTA GTA GTC GGT weeks of STZ treatment (Fig. 1A) , and none of the mice spontaneously recovered from STZ-induced diabetes.
mRNA Expression of Endodermal and Hepatic Markers To assess the differentiation of MSCs into hepatic lineages, we examined mRNA expression profiles. As shown in Fig. 1B , mRNA expression of endodermal markers, such as HNF4A, AFP, ERAS, CK18, and TTR was highly expressed. In addition, LST-1, ALB, TDO2, TAT, CPS1, and G6P, which are indicators of more mature hepatocytes were expressed.
Effects of Transplantation of BM-MSCs on Pancreas Histology Pancreata from the STZ-diabetic mice contained smaller islets (Fig. 2) , a decreased number of islets per section (Fig. 2) , and less mouse insulin immunoreactivity (Fig.  3) . Moreover, in Pancreata from induced BM-MSCs (iBMMSCs) and BM-MSCs groups, the islets appeared larger compared with islets from BM-MSCs-low, and PBS groups (Fig. 2) . In addition, in pancreas islets of control diabetic mice and normal groups, there were no BrdU-positive cells. In contrast, islets of iBM-MSCs and BM-MSCs groups (4 weeks after BMT) contained BrdU-positive cells in and around islets (Fig. 2) . Also, the islets of iBM-MSCs groups (4 weeks after BMT) had an increase in mouse insulin immunoreactivity (Fig. 3) . The number of islets per section in the iBM-MSCs group was significantly (pϽ0.05) higher than BM-MSCs, BM-MSCs-low, and PBS groups (Fig. 4A) .
Effects of Transplantation of BM-MSCs on Serum Insulin Levels
After an overnight fast, in iBM-MSCs group, the serum insulin levels were significantly increased (pϽ0.05) in comparison to BM-MSCs, BM-MSCs-low and diabetic control mice (Fig. 4B ). In addition, serum insulin levels from BM-MSCs-low, BM-MSCs and iBM-MSCs groups were significantly higher ( pϽ0.001) than diabetic control mice (Fig. 4B) .
Effect of Transplantation of BM-MSCs on Blood Glucose Levels
The blood glucose levels were monitored every 7 d after STZ treatment and following transplantation (Fig.  5A) . The blood glucose levels of BM-MSCs and iBM-MSCs groups significantly ( pϽ0.01) decreased 7 d after transplan- tation. The blood glucose levels of iBM-MSCs group were significantly (pϽ0.05) lower than BM-MSCs, BM-MSCslow, and PBS groups (Fig. 5A ) at 1, 2, and 3 weeks after transplantation. However, blood glucose levels of BMMSCs-low and BM-MSCs groups decreased more slowly than those in the iBM-MSCs groups.
Effect of Transplantation of BM-MSCs on Glucose Tolerance
Glucose tolerance test was performed on week 4 after transplantation (Fig. 5B) . The diabetic mice in BM- MSCs-low, BM-MSCs, and iBM-MSCs groups showed significant improvement in the glucose tolerance test compared with diabetic control mice (pϽ0.01).
Effect of Transplantation of BM-MSCs on Body Weight of Mice
Body weight of mice at weeks 0, 1, and 2 after transplantation was similar in all groups (Fig. 6A) . The significant increase in the weight of iBM-MSCs and BMMSCs groups was observed in comparison with BM-MSCslow and PBS groups at weeks 3 and 4 (pϽ0.05). In addition, in iBM-MSCs group body weight was significantly increased (pϽ0.05) compared to BM-MSCs, BM-MSCs-low and diabetic control mice.
Effects of Transplantation of BM-MSCs on Diabetic Mice Survival
The mice in each group were observed for their survival periods (Fig. 6B) . Most of the diabetic mice with sham surgery died 6-8 weeks after STZ treatment because they did not receive insulin treatment. The diabetic mice with cell transplant were killed 4 weeks after transplantation. The data shown in Fig. 6B indicates that in the iBMMSCs and BM-MSCs groups the mice survived much longer than the control diabetic (PBS) group (pϽ0.05).
DISCUSSION
Recent studies have demonstrated the feasibility of generating insulin-producing cells obtained from progenitor cells of various cellular sources including the pancreas, liver, and intestinal epithelium as well as pluripotent embryonic stem cells of mouse and human origin. 6) In this study, diabetes was induced in BALB/c mice with high-dose STZ. Without treatment, all diabetic mice remained diabetic (blood glucose Ͼ300 mg/dl), and no spontaneous reversal of diabetes was observed. This work demonstrates that transplantation of syngeneic induced MSCs can reverse STZ-induced diabetes in mice. This treatment of diabetic mice resulted in the repair of pancreatic islets. In addition, BrdU-positive cells were observed in the islets of iBM-MSCs and BM-MSCs groups. The blood glucose levels of iBM-MSCs group were significantly (pϽ0.05) lower than the other groups 2, 3, and 4 weeks after transplantation. In the iBM-MSCs group body weight and the number of islets was significantly increased (pϽ0.05) compared with BM-MSCs, BM-MSCs-low, and diabetic control mice. There was no significant difference between iBM-MSCs and BM-MSCs groups in glucose tolerance test and body weight. Our findings are in conflict with recent report, since transplantation with neither BM cells nor MSCs alone is sufficient for treatment of diabetes. 13) In agreement with our results, Lee et al. found that human MSCs alone were effective to treat diabetes in NOD/SCID mice injected with multiple low doses of STZ. 9) We also found that decreasing the number of MSCs to 1ϫ10 5 BMMSCs per animal reduced the reversing effect on hyperglycemia, number of islets, and body weight when transplanted in diabetic mice. This agrees with the recent report of Urbán et al. 13) The advantages of using MSCs are that they could be easily harvested, cultured and they might also be used as a source for autologous stem cells. 21) Also there is an additional attractive feature of BM-MSC, namely their ability to avoid allograft rejection, 22) which may allow the use of allogeneic BM-MSC if autologous cells could not be used. MSCs from both human and mouse have been shown to possess considerable plasticity and differentiate in vitro and in vivo into a variety of ectodermal, mesodermal, and endodermal tissues. 21, 23) MSCs from BM have been the most studied adult stem cells to date and several research groups have reported that BM-MSCs can differentiate into insulin-producing cells in vitro. 6, 21, [24] [25] [26] [27] In addition, several in vivo studies have demonstrated that BM-MSCs transplanted into diabetic mice contribute to pancreatic regeneration. Portal vein transplantation of islet-like cells differentiated from rat BMMSCs could alleviate the hyperglycemia of diabetic rats. 28) MSC administration resulted in pancreatic islets regeneration and prevented renal damage in type 1 diabetic mice. 16) In addition, a recent study has demonstrated that infusion of human MSC in NOD/SCID mice after STZ-induced pancreatic damage enhances the number of endogenous mouse b cells, with consecutive increase of circulating mouse insulin and improvement of hyperglycemia. 9) There are studies which support the hypothesis that BM-derived hematopoietic and/or MSCs can promote islet regeneration in diabetic animals. 13) In addition, recent findings provide evidence for a supportive role of BM cells in islet regeneration, rather than transdifferentiation of BM into insulin-producing cells. 21) In recent years, several studies have showed that MSCs transplantation can improve hyperglycemia. Transdifferentiation of MSCs into insulin-producing cells has ever been regarded as the main mechanism. Researchers have found that MSCs naturally produce a variety of cytokines and growth factors, promoting the survival of surrounding cells by paracrine mechanisms. 29) MSCs have also been noted to have immunomodulatory effects. Indeed, some of the initial observations regarding MSC protection from tissue injury once thought mediated by tissue regeneration may actually result from immunomodulation. 30) Because the pancreas and liver have common precursor cells during embryogenesis, stem cells of these two organs may have the same origin. 31) Therefore, liver stem cells would be another attractive source for new b-cells. Yang et al. presented evidence that highly purified adult rat hepatic oval cells could transdifferentiate into pancreatic cells when cultured in a high-glucose environment and reversed hyperglycemia in a diabetic NOD/SCID mice. 31) A number of in vivo and in vitro studies have demonstrated that liver cells can be induced to express markers and adopt some functional aspects of b-cells. In a recent study rat MSCs were cultured in the presence of HGF and FGF-4 and expressed genes specific to pancreatic b-cells as well as those specific to hepatocytes. 32) Persistent expression of the pancreatic duodenal homeobox-1 (Pdx1) transcription factor in fetal and adult hepatic cells reprograms these cells into pancreatic b-cell precursors. Upon transplantation into diabetic mice, these cells become functional insulin-producing cells and restore euglycemia. 31, [33] [34] [35] In addition, it has been reported that human fetal liver cells, which express markers of hepatocytes, bile duct cells, and oval cells are capable of differentiation into mature hepatocytes in vivo. 36) Other studies demonstrate that liver cells could thus provide another clinically relevant source of precursors to be used for generation of transplantable insulin-producing cells. 37, 38) However, to our knowledge no one has reported the effect of transplantation of MSCs induced into endoderm and early hepatic cells into STZ-diabetic mice. The results of the present study demonstrate that transplantation of BM-derived MSCs induced into endoderm and early hepatic cells promotes pancreatic islet repair in diabetic mice.
